RLS-0071 clinical trials
Also written RLS-0071.
How each study uses RLS-0071 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the RLS-0071 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RLS-0071
- 4
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
ReAlta Life Sciences, Inc. (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test RLS-0071, phase 3 first.
- Dec 2026A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic HypothermiaPhase 2/3 · ReAlta Life Sciences, Inc.
- Dec 2026Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host DiseasePhase 2 · ReAlta Life Sciences, Inc.
Studies
Open first, then newest update. How each study uses RLS-0071 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic HypothermiaRecruitingPhase 2/3ReAlta Life Sciences, Inc.NCT05778188Written as RLS-0071
- Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host DiseaseRecruitingPhase 2ReAlta Life Sciences, Inc.NCT06343792Written as RLS-0071
- Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseActive, not recruitingPhase 2ReAlta Life Sciences, Inc.NCT06175065Written as RLS-0071
- A Clinical Study to Determine the Safety, Tolerability and Effect of RLS-0071 Doses When Given to Healthy Adults After Inhaling LPSCompletedPhase 1ReAlta Life Sciences, Inc.NCT05351671Written as RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)
- A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development ProgramCompletedPhase 1ReAlta Life Sciences, Inc.NCT05298787Written as RLS-0071
- A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory FailureWithdrawnPhase 1ReAlta Life Sciences, Inc.NCT04574869Written as RLS-0071 10 mg/kg
Codes
What other systems call RLS-0071 · ClinicalTrials.gg INT001859
- MeSH (NLM) C000722534RLS-0071One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722534 | RLS-0071 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.